Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
Recap by typeshit. Post by @YaleMedicine on X.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
8:32
Archibald follows up his earlier retatrutide video with a look at its uses. Retatrutide is still an investigational drug and is not FDA approved.
Bynes explains in her own words why she began Ozempic after stepping away from her acting career. Short celebrity item with little beyond the quote.
Bikman argues the facial change reflects rapid weight loss in general and suggests using the drug as a short-term aid for carb cravings. His view, not settled fact.
Loading…